Fiduciary Management Inc. WI Sells 250,915 Shares of Smith & Nephew SNATS, Inc. $SNN

Key Points

• Fiduciary Management Inc. WI reduced its stake in Smith & Nephew SNATS, Inc. by 6.3% in Q1, now owning approximately 3.75 million shares worth $106.32 million.
• Several institutional investors significantly increased their stakes, with Bessemer Group Inc. raising its stake by 3,471.4%.
• The average analyst rating for Smith & Nephew is currently "Hold" with a consensus target price of $36.00, which reflects recent adjustments in ratings and price objectives.

Fiduciary Management Inc. WI decreased its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 6.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,747,726 shares of the medical equipment provider's stock after selling 250,915 shares during the quarter. Fiduciary Management Inc. WI owned 0.86% of Smith & Nephew SNATS worth $106,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Hexagon Capital Partners LLC increased its stake in Smith & Nephew SNATS by 63.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after acquiring an additional 406 shares during the last quarter. GAMMA Investing LLC increased its stake in Smith & Nephew SNATS by 22.4% in the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after acquiring an additional 666 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Smith & Nephew SNATS by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,281 shares of the medical equipment provider's stock worth $434,000 after acquiring an additional 672 shares during the last quarter. Marotta Asset Management increased its stake in Smith & Nephew SNATS by 6.4% in the 1st quarter. Marotta Asset Management now owns 12,613 shares of the medical equipment provider's stock worth $393,000 after acquiring an additional 764 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Smith & Nephew SNATS by 8.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,923 shares of the medical equipment provider's stock worth $282,000 after acquiring an additional 803 shares during the last quarter. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Trading Up 1.5%

Shares of Smith & Nephew SNATS stock traded up $0.5630 on Friday, reaching $37.5330. The company had a trading volume of 603,940 shares, compared to its average volume of 989,200. The firm has a market cap of $16.44 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 1.03 and a beta of 0.68. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The firm's 50-day moving average price is $31.96 and its two-hundred day moving average price is $29.27. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $37.58.

Smith & Nephew SNATS Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a dividend of $0.285 per share. This represents a dividend yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS's dividend payout ratio (DPR) is currently 41.20%.

Analysts Set New Price Targets

SNN has been the topic of a number of research reports. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research note on Monday, August 18th. Wall Street Zen cut Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a report on Friday. Six investment analysts have rated the stock with a Hold rating, According to MarketBeat, Smith & Nephew SNATS presently has an average rating of "Hold" and a consensus price target of $36.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.